Chemistry:PF-219,061
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Nasal |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H19NO2 |
| Molar mass | 221.300 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It was under development as a potential medication for the treatment of female sexual dysfunction.[3][4] It did not advance into clinical trials.[5]
See also
- ABT-670
- ABT-724
- Cabergoline
- Bremelanotide
- Flibanserin
- Intrinsa
- Melanotan II
- OSU-6162
- PF-592,379
- Pramipexole
- Tibolone
- UK-414,495
References
- ↑ "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route". Bioorganic & Medicinal Chemistry Letters 17 (24): 6691–6. December 2007. doi:10.1016/j.bmcl.2007.10.059. PMID 17976986.
- ↑ "Dopamine D4 receptors and the regulation of penile erection". Drug Discovery Today: Therapeutic Strategies 3 (4): 599–604. 2006. doi:10.1016/j.ddstr.2006.10.006.
- ↑ Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO/2003/051370, granted to Pfizer[yes|permanent dead link|dead link}}]
- ↑ "Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061". Xenobiotica; the Fate of Foreign Compounds in Biological Systems 39 (7): 523–33. July 2009. doi:10.1080/00498250902893775. PMID 19480558.
- ↑ "Targeting the dopamine D3 receptor: an overview of drug design strategies". Expert Opinion on Drug Discovery 11 (7): 641–64. July 2016. doi:10.1080/17460441.2016.1185413. PMID 27135354.
 |  |
